Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 10,539 Shares

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 10,539 shares of the stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the transaction, the insider directly owned 354,388 shares in the company, valued at approximately $2,533,874.20. This represents a 2.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Evolus Price Performance

EOLS traded down $0.24 on Monday, hitting $6.66. The company had a trading volume of 742,236 shares, compared to its average volume of 1,126,954. The stock has a market cap of $431.70 million, a price-to-earnings ratio of -7.24 and a beta of 0.87. The company’s fifty day moving average price is $6.91 and its 200 day moving average price is $7.51. Evolus, Inc. has a 1-year low of $5.71 and a 1-year high of $17.12.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.05. Evolus had a negative return on equity of 759.04% and a negative net margin of 20.49%.The company had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. On average, sell-side analysts forecast that Evolus, Inc. will post -0.61 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on EOLS shares. Mizuho cut their target price on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Monday, December 1st. BTIG Research reiterated a “buy” rating and issued a $18.00 price objective on shares of Evolus in a research note on Monday, September 8th. Wall Street Zen upgraded Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently made changes to their positions in EOLS. Frazier Life Sciences Management L.P. bought a new position in Evolus during the second quarter valued at about $22,431,000. Nantahala Capital Management LLC lifted its position in shares of Evolus by 33.2% in the 3rd quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock worth $35,163,000 after acquiring an additional 1,428,931 shares during the period. Soleus Capital Management L.P. grew its holdings in shares of Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. Caligan Partners LP increased its position in shares of Evolus by 23.8% during the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares during the period. Finally, Pinnacle Associates Ltd. bought a new stake in shares of Evolus during the second quarter valued at approximately $6,318,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.